Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)
Status:
Completed
Trial end date:
2011-08-11
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant
(MK-4305) on respiratory function in participants with mild to moderate obstructive sleep
apnea (OSA) compared to administration of placebo. The primary hypothesis of this study is
that multiple doses of MK-4305 do not produce a clinically significant increase in
Apnea-Hypopnea Index (AHI) in participants with mild to moderate OSA, as compared to placebo.